Find an expert

Dr Will Anderson is a Research Fellow at The University of Queensland, specialising in molecular diagnostics, nanoparticle characterisation, and translational device development. His current work focuses on developing diagnostics for single molecule quantitation and low-cost, accessible technologies for nucleic acid analysis.

Dr Anderson has over 15 years of R&D experience spanning academia and industry, with expertise in:

• Nanopore sensing and nanoparticle analysis

• Nucleic acid extraction and quantification

• Diagnostic device prototyping and point-of-care platforms with a focus on fluorescence-based detection

• Research translation, IP strategy, and regulatory frameworks

Dr Anderson’s work bridges fundamental research and real-world application, with a strong focus on enabling diagnostic innovation through mechatronics, assay development, and collaborative industry engagement.

Dr Kevin M. Koo is currently a National Health and Medical Research Council (NHMRC) Investigator Fellow and Prostate Cancer Foundation of Australia (PCFA) Future Leader Fellow at The University of Queensland (UQ). Dr Koo was awarded his PhD (Dean’s Award for Outstanding Thesis & Springer Thesis Prize) from the Australian Institute for Bioengineering & Nanotechnology (AIBN), UQ in 2018.

Post-PhD, he begun a productive postdoctoral career with dual industry/academia appointments: as the Head of Assay Development/Lab Director in XING Technologies Pty Ltd (a Brisbane-based biotech start-up) to undertake product development projects for commercialization of disease in vitro diagnostics, and as an Honorary Fellow/Principal Research Scientist at UQ Centre for Clinical Research (UQCCR) to continue his academic research in precision cancer nanodiagnostics. His research skills and experiences are honed through dedicated career time spent in both academic research and regulated industry environments.

Dr Koo's research encompasses multi-disciplinary fields of molecular biomarker and nanobiosensor development, translation, and commercialization for precision disease management applications. Presently, he is working on the design and development of integrated multi-bioanalyte sensing technologies to resolve the various challenges around holistic disease pathway understanding and clinical biomarker profiling.

Dr Koo's research endeavours have been recognized by a Metrohm Australia-New Zealand Young Chemist Award (2018), Australian Institute of Policy & Science (AIPS) Queensland Young Tall Poppy Science Award (2023) and UQ Faculty of Medicine "Rising Star of the Year" Excellence Award (2024).

Teaching

UQ School of School of Chemistry and Molecular Biosciences (SCMB)

BIOT7018 Biologics: Course Coordinator 2025-2026

BIOC7001 Advanced Molecular Biology Laboratory: Guest Lecturer 2024-2025

BIOC6001 Introduction to Molecular Biology Laboratory: Guest Lecturer 2024

Associate Professor Arutha Kulasinghe leads the Clinical-oMx Lab at the Frazer Institute, University of Queensland and is the Founding Scientific Director of the Queensland Spatial Biology Centre (QSBC) at the Wesley Research Institute. A/Prof Kulasinghe has pioneered spatial transcriptomics, proteomics, and interactomics in the Asia-Pacific region, contributing to world-first studies in lung cancer, head and neck cancer, and tissue atlasing studies of infectious diseases across pandemics. His research aims to understand the underlying pathobiology by using an integrative multi-omics approach. A/Prof Kulasinghe has over 100 peer-reviewed publications, including The Lancet Microbe, Journal of Clinical Oncology and Nature Genetics. He is the recipient of the Cure Cancer "Researcher of the Year" 2023 and named in the "Top Innovators Award" by the Australian for 2024. A/Prof Kulasinghe is supported by the MRFF, NHMRC, US DoD, Cancer Australia, Cure Cancer, pharma and numerous hospital and philanthropic organisations.

Dr Mostafa Kamal Masud is a CCQ Next Generation Cancer Research Fellow at the Australian Institute for Bioengineering & Nanotechnology (AIBN), the University of Queensland (UQ). In 2020, he received his PhD in Medical Biotechnology Diagnostics and Nanobiotechnology from AIBN, UQ. He received his MS and B.Sc. (Hons.) in Chemistry from Shahjalal University of Science and Technology (SUST), Sylhet-3114, Bangladesh. After completing his PhD, he was awarded a prestigious JSPS Postdoctoral Fellowship (success rate >10%) from Japan and served as a Postdoctoral Fellow at Japan's National Institute for Materials Science (NIMS).He recently been awarded a highly prestigious ARC DECRA fellowship for the period 2024-2026 and a QLD Cancer Council fellowship for the period 2024–2028. His research focuses on the development of novel nanostructures and nanodiagnostic technologies to address critical issues in medical diagnosis. As an early career researcher, he has an excellent track record with more than 60 peer-reviewed publications in prestigious and high-impact journals in the area that achieve <2800 citations with an h-index of 29 (Scholar google link: https://bit.ly/2Vtv67l). He has developed new classes of superparamagnetic nanostructures and fabricated novel biosensors for the detection of disease-specific biomolecular targets e.g., for miRNA, DNA, exosome and protein biomarker detection that have proven to be easy and effective, allowing for rapid diagnosis with minimal equipment. He made a major contribution to nanotechnology integrated-analytical and diagnostic fields by providing analytical and technological input as well as developing key collaborations with clinicians and biologists for translational research. His strategy is to create nano-architecture point-of-care diagnostic technology for early diagnosis of cancer that could hopefully lead to a healthy and happier life for humans.

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland, where he leads the Genomics and Machine Learning (GML) Laboratory. His research focuses on understanding pathological processes within tissues to identify biomarkers for early diagnosis, patient stratification, and prediction of treatment response. His work integrates statistical machine learning techniques with advanced genomic technologies, combining single-cell and spatiotemporal sequencing data with tissue imaging to uncover causal links between genotypes and phenotypes across biological scales, from single cell, to tissue microenvironment, organ, multi-organ and population level. By studying cell-cell interactions, his research also contributes to the discovery of novel drug targets and improved understanding of drug mechanisms and toxicity. The GML Laboratory also develops spatiotemporal experimental platforms for large-scale biomarker profiling and validation in preclinical models and patient cohorts.

Dr Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship in 2021, and is a National Health and Medical Research Council leadership fellow. He has authored 86 publications in top-tier journals, like Cell, Nature Genetics, and Nature Method, averaging ~45.5 citations per paper, and led the development of 14 software tools with over 250,000 downloads. His recognised expertise is demonstrated through 14 national/international awards, numerous invited talks (21 international, 42 national), invited grant reviews for funding bodies in nine countries, and active editorial roles for BMC Cancer and Genome Medicine. His commitment to propelling the field forward is evident in leading roles within key consortia and forums and his dedication to organise training workshops and conferences. He has secured over $31 million in grant funding as a chief investigator from national and international funding agencies (e.g., ARC, NHMRC, MRFF, DoD, NCI) and from industry partners, with approximately $11million directly supporting his lab's groundbreaking work.